Global healthcare company Sanofi will become the first tenant of the Translational Research Institute’s (TRI) new ENTRI biomanufacturing facility in Brisbane, the Institute announced, marking what it described as a significant milestone for Queensland’s biomedical sector.
In a news release, TRI said Sanofi’s tenancy forms part of a broader expansion of the Translational Science Hub, which links local researchers with the company’s international scientific teams in France and the United States.
According to TRI, Sanofi’s presence at ENTRI is expected to support the growth of the state’s biomedical ecosystem by contributing expertise in product development, clinical research and commercialisation.
TRI CEO Professor Maher Gandhi said Sanofi’s early commitment to the facility reinforces the Institute’s long-term vision for a fully integrated translational pathway in Queensland.
“Sanofi’s commitment to ENTRI represents a ringing endorsement of the facility and importantly an affirmation of our vision for a complete translational pathway from discovery, all the way through to manufacturing products to undertake clinical trials for the benefit of patients,” Professor Gandhi said.
“ENTRI is the key to achieving this by helping to remove barriers to entry for biotech companies and Sanofi’s presence will add enormous value to that vision.”
Sanofi is a partner in the Translational Science Hub alongside The University of Queensland, Griffith University and the Queensland Government.
TRI stated the Hub aims to strengthen collaboration between international and Australian scientific teams to accelerate new medical innovations.
Professor Cameron Simmons, Sanofi’s Head of the Translational Science Hub, said the company’s decision to take tenancy at ENTRI reflects its long-term investment in local scientific capability.
“Our decision to establish a presence at ENTRI demonstrates Sanofi’s long-term commitment to Queensland and Australia,” Professor Simmons said.
“Through the Translational Science Hub, we aim to foster collaboration between global and local experts, creating a scientific community focused on new medical technology and translational science.”
The ENTRI facility is scheduled to open in early 2026. TRI said it will provide access to cGMP cleanrooms, wet laboratories, office space and collaboration areas designed to support maturing companies in manufacturing products for all phases of clinical trials.
The project is jointly funded by TRI and the Queensland Government.
Professor Gandhi said the establishment of ENTRI represents a significant advancement in building clinical trial and manufacturing capability within the state.
“Among my ambitions for TRI is to see in-house clinical trials being conducted from therapeutics and medical devices that have been discovered and developed here,” he said.
“ENTRI is a major step towards that vision, enabling translation of research from the bench to the bedside by manufacturing products for clinical trials right here in Queensland.”
